Nationality: Italian | Year of Birth: 1974

Giovanni Di Napoli was appointed executive director and CEO at Cosmo Pharmaceuticals NV as of May 2024.

Giovanni Di Napoli is an accomplished Healthcare Executive with over 20 years of experience in Life Sciences spanning entrepreneurial ventures and corporate environments. During my tenure leading Medtronic’s Gastrointestinal (GI) Operating Unit (OU), he spearheaded remarkable growth from a two-product niche OU to a global OU encompassing approximately 20 products across three portfolios. This expansion significantly contributed to Medtronic’s $32 billion revenue, achieved through the implementation of a direct sales model, team restructuring, internal innovation, and strategic acquisitions, all aligned with the overarching vision of advancing patient health worldwide.

As President of the GI OU, he helped to pioneer the integration of AI into the GI field, earning recognition from Forbes Magazine for innovative contributions in March ’21 as a co-author of the article “The brave new world of artificial intelligence: dawn of a new era.”

Moreover, he led the acquisition of the PillCam business worth approximately $1 billion as part of the larger acquisition of Covidien by Medtronic.

With oversight of all GI operations, including P&L management and employee well-being across various departments such as Sales, Marketing, Quality, Business Development, Research & Development, Clinical, Regulatory, and among others, he prioritized diversity and inclusion, achieving a 42.4% diverse representation, consistently surpassing corporate standards.

Beyond his professional endeavors, Giovanni is committed to raising awareness of colon and esophageal cancer through collaborations with the Colon Cancer Alliance and Esophageal Cancer Association. Additionally, he contribute to the public community as part of Medtronic’s STEM project and personally support children’s education initiatives. Giovanni has received recognition such as the ASGE Crystal Award for contributions to the field of GI and regularly participate as a speaker at conferences globally, including in Silicon Valley and medical device and tech summits.

Nationality: Russian/USA | Year of Birth: 1982

Svetlana Sigalova was appointed Chief Financial Officer of Cosmo, effective November 11, 2024.

Svetlana brings a wealth of experience from senior financial roles at global pharmaceutical and biotech companies. As Vice President of Commercial Finance at Moderna, she led financial operations for over $6 billion in global sales, developing financial infrastructure and planning systems that were pivotal in Moderna’s rapid growth during the pandemic.

Prior to Moderna, Svetlana held senior finance leadership positions at Alexion Pharmaceuticals and Vertex Pharmaceuticals, where she managed multibillion-dollar revenue streams, built high-performance finance teams, and drove operational efficiency.

Nationality: American | Year of Birth: 1966

Diana is President Dermatology Division at Cosmo since January 2022 and formerly CEO of Cassiopea SPA since May 2015.

Diana brings 30 years of cross-functional experience in the pharmaceutical industry, including 20 years in the dermatology sector. She has held executive positions at leading pharmaceutical companies, including 17 years at Medicis Pharmaceutical Corporation, an industry-leading dermatology and aesthetics company, ultimately serving as the Vice President of Corporate Development. Earlier in her career, she spent 10 years in various roles at Abbott Laboratories, in marketing, business development and operations across Abbott’s pharmaceutical, hospital products and diagnostic divisions.

Ms. Harbort has a bachelor’s degree in Business Administration from the University of Wisconsin Whitewater and an MBA in Marketing and Management from the Northwestern University Kellogg School of Management. She currently is a member of the American Academy of Dermatology and the Women’s Dermatological Society.

Nationality: Italian | Year of Birth: 1979

Nhan is President of Cosmo Intelligent Medical Devices.

With a computer science background, he began his career in 2000 as an IT specialist in the Neuroimaging Laboratory of the University La Sapienza of Rome. Since 2002 he has been leading development projects for products, applications, and services in several medical specialties, most notably in radiology, neurology, gastroenterology, and medical photography among others. He led teams to successfully develop innovative hardware and software solutions for hospitals, CROs, Pharmaceutical and Biotech companies with a wide variety of application contexts and technological platforms, including Artificial Intelligence.

Nationality: Italian | Year of Birth: 1973

Andrea Cherubini is Chief AI Officer (CAIO) at Cosmo Pharmaceuticals NV, leading AI innovation across the company’s portfolio, from drug development to medical devices and digital health.

Previously, he was SVP of Science, AI, and Data at Cosmo IMD, focusing on AI solutions for intelligent medical devices. He began his career in neuroimaging research at Fondazione Santa Lucia, later becoming a Tenured Researcher in Biomedical Imaging at the Italian National Research Council (CNR) and a Lecturer in Physics at Magna Graecia University. In 2018, he joined Linkverse as Head of AI, specializing in medical imaging and diagnostics.

Andrea holds a Laurea degree in Physics from La Sapienza University and a Ph.D. in Biomedical Engineering from Magna Graecia University.

Nationality: Czech | Year of Birth: 1986

Dominika Spilarova was appointed Chief Strategy Officer of Cosmo Pharmaceuticals, effective January 10, 2025. Dominika will report directly to the CEO and also serve as acting Chief of Staff for the executive leadership team until a permanent appointment for this position is made.

Dominika brings over 15 years of diverse experience both within and outside the Life Sciences industry, combined with a strong background in management consulting with PwC and independent consulting globally. Over the course of her career, she has successfully developed and implemented innovative strategies that have delivered measurable outcomes, including the launch of new product offerings, revenue growth, and operational efficiencies. Her contributions have positively impacted businesses ranging in size from $26 million to $19.5 billion in revenue. Before joining Cosmo, Dominika was the founder and managing director of her own Life Sciences consulting business.

She has extensive expertise in building and leading high-performing teams, from small agile groups to teams of over 50 members. Her coaching qualifications enable her to help employees unlock their potential, both individually and collectively. Passionate about advancing women in the workplace, Dominika actively contributes through her not-for-profit coaching work and as a member of the “Forbes Forum for Female Leaders.”

Dominika’s comprehensive understanding of the end-to-end value chain in Life Sciences equips her to drive tangible strategy execution across all levels of Cosmo, ensuring sustainable growth and operational excellence.

Nationality: Lithuanian | Year of Birth: 1982

Egle Gedrimaite was appointed Head of Global Business Development, at Cosmo Pharmaceuticals NV as of October 2024.

Egle brings 15 years of experience as Business Development director and Alliance management in pharmaceutical, medical device and nutraceutical industries. Her expertise ranges from developing successful business both in B2B and B2C sectors, steering the growth of both established and newly developed products.

Her cross-functional attitude and experience brings her to drive development projects from inception to completion, working in collaboration with all corporate functions to ensure a successful outcome. She has previously worked for Sofar and Alfasigma.

Egle holds a degree in International Communications and Communication Systems in International Relations from the Università per Stranieri di Perugia (Italy).